Onctura, a clinical-stage biopharmaceutical company developing precision oral small molecules for neglected and hard-to-treat cancers, today announces that its Chief Executive Officer, Catherine ...

Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with ...

Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...

GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...

Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...

Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.

Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 ...

To request an in-person meeting with Gain management on Wednesday during the week of the J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with ...

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to co ...

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to ...

LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to ...